hit counter
Avid Bioservices, Inc. (CDMOP) Stock News Sentiment & Price - Sentifly
CDMOP - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Avid Bioservices, Inc. (CDMOP)

USA
Biotechnology
NASDAQ
CDMOP Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CDMOP Latest news
Seeking Alpha
Neutral
Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript
2021-06-29 23:11

Avid Bioservices, Inc. (CDMO) CEO Nick Green on Q4 2021 Results - Earnings Call Transcript

GlobeNewsWire
Neutral
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2021 and Recent Developments
2021-06-29 16:05

-- Recorded Fourth Quarter Revenue of $27.6 Million and Annual Revenue of $95.9 Million -- -- Achieved Four Consecutive Quarters of Operational Profitability During Fiscal 2021 --

GlobeNewsWire
Neutral
Avid Bioservices to Report Financial Results For Quarter and Fiscal Year Ended April 30, 2021 After Market Close on June 29, 2021
2021-06-22 16:05

TUSTIN, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2021 on June 29, 2021 after market close and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and FY ended April 30, 2021 and review recent corporate developments.

Zacks Investment Research
Neutral
Avid Bioservices (CDMO) Q4 Earnings Preview: What's in the Cards?
2021-06-22 15:47

Avid Bioservices (CDMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research
Positive
Avid Bioservices (CDMO) Stock Jumps 7.2%: Will It Continue to Soar?
2021-06-04 05:16

Avid Bioservices (CDMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

GlobeNewsWire
Neutral
Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics' ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)
2021-05-25 08:05

ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)

Zacks Investment Research
Positive
Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?
2021-04-27 11:17

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

GlobeNewsWire
Neutral
Avid Bioservices Announces Completion of Redemption of Series E Convertible Preferred Stock
2021-04-15 16:05

TUSTIN, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (the “company”), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that it has completed the redemption of all of the company's outstanding 10.50% Series E Convertible Preferred Stock (“Series E Preferred Stock”) as of April 12, 2021 (the “Redemption Date”).

Zacks Investment Research
Positive
Avid Bioservices' (CDMO) Shares March Higher, Can It Continue?
2021-04-06 10:36

As of late, it has definitely been a great time to be an investor in Avid Bioservices, Inc. (CDMO).

GlobeNewsWire
Neutral
Avid Bioservices to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
2021-03-17 08:05

TUSTIN, Calif., March 17, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced that the company will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Nick Green, president and chief executive officer of Avid Bioservices, will be the featured speaker in a fireside chat at the conference, which will take place March 23-24, 2021 in a virtual format.

Loading more news...